Evidence map›Paper›PMID 40659617›Full record

ArticleNature communications2025

Deep-tissue high-sensitivity multimodal imaging and optogenetic manipulation enabled by biliverdin reductase knockout.

Ludmila A Kasatkina, Chenshuo Ma, Huaxin Sheng, Matthew Lowerison, Luca Menozzi, Mikhail Baloban, Yuqi Tang, Yirui Xu, Lucas Humayun, Tri Vu and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Ludmila A Kasatkina *Department of Genetics and Gruss-Lipper Biophotonics Center, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID http://orcid.org/0000-0003-3935-5389
Chenshuo Ma *Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.
Huaxin ShengDepartment of Anesthesiology, School of Medicine, Duke University, Durham, NC, USA.
Matthew LowerisonDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.
Luca MenozziDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.ORCID http://orcid.org/0000-0001-7542-1051
Mikhail BalobanDepartment of Genetics and Gruss-Lipper Biophotonics Center, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID http://orcid.org/0000-0003-3919-1222
Yuqi TangDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.
Yirui XuDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.
Lucas HumayunDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.
Tri VuDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.
Pengfei SongDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA.ORCID http://orcid.org/0000-0002-9103-6345
Junjie YaoDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, USA. junjie.yao@duke.edu.ORCID http://orcid.org/0000-0002-2381-706X
Vladislav V VerkhushaDepartment of Genetics and Gruss-Lipper Biophotonics Center, Albert Einstein College of Medicine, Bronx, NY, USA. vladislav.verkhusha@einsteinmed.edu.ORCID http://orcid.org/0000-0002-2083-8121

Funding

INNOVATIONS IN SHOCK WAVE LITHOTRIPSY TECHNOLOGYR01DK052985 · NIDDK · DUKE UNIVERSITY · PI ZHONG, PEI · 1997 to 2025
$6.1M
Innovations in Shock Wave Lithotripsy TechnologyR37DK052985 · NIDDK · DUKE UNIVERSITY · PI ZHONG, PEI · 2010 to 2019
$5.9M
DART.3-Revolutionizing Neuropsychiatric Treatment through Noninvasive, Programmable Cell-Type-Specific NeuropharmacologyR01MH135932 · NIMH · DUKE UNIVERSITY · PI Michael R Tadross · 2024 to 2026
$4.4M
Near-Infrared Fluorescent Proteins, Biosensors and Optogenetic ToolsR35GM122567 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Vladislav Verkhusha · 2017 to 2026
$4.3M
High-resolution High-speed Photoacoustic and Ultrasound Imaging of SmallVessel Functions in Ischemic StrokeR01NS111039 · NINDS · DUKE UNIVERSITY · PI YAO, JUNJIE · 2019 to 2023
$2.7M
High-throughput Imaging-integrated Vascular Model for Understanding Thromboembolism and Therapeutics ScreeningR01HL166522 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Junjie Yao, Y. Shrike Zhang · 2023 to 2026
$2.7M
High-Throughput Volumetric Photoacoustic Imaging of Living Vascularized OrganoidsR01EB028143 · NIBIB · DUKE UNIVERSITY · PI YAO, JUNJIE · 2019 to 2022
$2.0M
3D real-time super-resolution cavitation mapping in laser lithotripsy of urinary stone diseaseR01DK139109 · NIDDK · DUKE UNIVERSITY · PI Michael E Lipkin, Junjie Yao · 2024 to 2026
$1.8M
Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) GM122567NHLBI NIH HHS R01 HL166522NIBIB NIH HHS R01 EB028143NIDDK NIH HHS R01 DK052985NIDDK NIH HHS R01 DK139109NIDDK NIH HHS R37 DK052985NIGMS NIH HHS R35 GM122567NIMH NIH HHS R01 MH135932NINDS NIH HHS R01 NS111039
6 · The paper itself

Abstract

Performance of near-infrared probes and optogenetic tools derived from bacterial phytochromes is limited by availability of their biliverdin chromophore. To address this, we use a biliverdin reductase-A knock-out mouse model (Blvra

Indexed as

Multimodal ImagingOptogeneticsOxidoreductases Acting on CH-CH Group DonorsAnimalsBiliverdineBrainMaleMiceMice, Inbred C57BLMice, KnockoutMicroscopy, Fluorescence, MultiphotonNeuronsPhotoacoustic TechniquesBiliverdinebiliverdin reductaseOxidoreductases Acting on CH-CH Group Donors

Identifiers

PMID40659617
PMCPMC12260061

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.